Taken together, our data clearly demonstrate that PRDX1-mediated CUL5 neddylation and subsequent NOXA degradation must be one of the strategies by which CRC cells counteract the toxic effect of chemotherapeutics (Fig. 7H). Here, PRDX1 is linked to colorectal carcinoma.